Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01702311 · ClinicalTrials.gov registry record · NA

Point-of-Care Glucose Testing and Insulin Supplementation

A NA study, sponsored by Emory University.

Completed
Registry status
NA
Development phase
235
Enrollment target

NCT01702311: Completed NA study, sponsored by Emory University.

NCT01702311 is a NA study that has completed, run by Emory University. The registered enrollment target is 235 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01702311, a NA study, has completed, sponsored by Emory University.

COMPLETED
Registry status
NA
Development phase
235 participants
Enrollment target

Study Summary

Capillary point-of-care (POC) testing is advocated as a valuable aid in the management of diabetes and hyperglycemia in the hospital setting. POC testing aims at collecting information on BG levels at different time points during the day in order to assess glycemic control and to guide insulin adjustment/correction doses. Although POC testing provides insights into day-to-day excursions in BG levels, bedtime BG testing triggers the use of insulin supplements that may result in increased frequency of hypoglycemia and is expensive with an estimated annual cost in hospitals of several hundreds of millions of dollars in the U.S. Accordingly, this pilot study aims to assess the utility of POC and insulin supplementation (correction doses) at bedtime in improving glycemic control and in preventing hypoglycemia in non-ICU patients with type 2 diabetes mellitus (T2DM). A total of 250 non-ICU medical and surgical patients treated with basal bolus regimen will undergo POC testing before meals and bedtime (standard of care) and half of the patients will receive insulin correction doses at bedtime for BG \> 140 mg/dL following a sliding scale protocol, while the other half will be followed without insulin supplementation at bedtime except for extreme hyperglycemia (BG \> 350 mg/dl). Patients will be recruited at Emory University Hospital and Grady Memorial Hospital.

Primary Outcome

The primary outcome of the study is to compare differences in mean fasting blood glucose levels between patients receiving insulin supplements at bedtime compared to those without insulin supplementation.

Interventions

  • DRUG Bedtime insulin Aspart (Novolog)

Trial Details

FieldValue
Enrollment Target 235 participants
Start Date 2012-05
Est. Completion 2013-12
Phase NA
Emory University

1,208 total trials

What the finished NCT01702311 record still lists

NCT01702311 is an interventional study that assigns participants to a tested intervention. The registered 235 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).

The record links to 0 conditions, and to 1 intervention - of which Bedtime insulin Aspart (Novolog) is the first listed.

NCT01702311 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01702311 about?

NCT01702311 is a clinical study titled "Point-of-Care Glucose Testing and Insulin Supplementation". Capillary point-of-care (POC) testing is advocated as a valuable aid in the management of diabetes and hyperglycemia in the hospital setting. POC testing aims at collecting information on BG levels at different time points during the day in order to assess glycemic control and to guide insulin adjus...

What is the current status of trial NCT01702311?

This trial is currently completed. It is a NA study. The enrollment target is 235 participants. The study started on 2012-05. Estimated completion is 2013-12.

What interventions are being tested in trial NCT01702311?

The interventions under investigation include: Bedtime insulin Aspart (Novolog) (DRUG).

Who is sponsoring clinical trial NCT01702311?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01702311's enrollment target sits among peer trials

235 461st of 2000 higher than 1,539 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01524211 · 235 participants · NA

    Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms

  • NCT05316155 · 235 participants · Phase 1

    Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  • NCT05353569 · 235 participants · NA

    Coherent Optical Detection of Middle Ear Disease

  • NCT05390918 · 235 participants · NA

    Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01702311, the US trial registry maintained by the National Library of Medicine. NCT01702311 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.